# SSRIs and SNRIs in Pediatric Practice: Indications and Monitoring

## Introduction

Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are the most commonly prescribed psychotropic medications in pediatric mental health. They represent first-line pharmacotherapy for depressive and anxiety disorders in children and adolescents. However, their use requires careful attention to FDA indications, the black box warning on suicidality, developmental pharmacology, and systematic monitoring protocols.

## Mechanism of Action

### SSRIs

SSRIs selectively inhibit the serotonin transporter, blocking presynaptic serotonin reuptake and increasing synaptic serotonin availability in key circuits including the prefrontal cortex, amygdala, and hippocampus. The therapeutic effects are not immediate; downstream changes in receptor desensitization and neuroplasticity develop over two to six weeks. The medications in this class include fluoxetine, sertraline, escitalopram, citalopram, fluvoxamine, and paroxetine.

### SNRIs

SNRIs inhibit reuptake of both serotonin and norepinephrine through dual transporter blockade. Norepinephrine reuptake inhibition is more pronounced at higher doses. The medications in this class include venlafaxine, duloxetine, and desvenlafaxine. The dual mechanism provides additional benefit for pain-related conditions and somatic symptom presentations.

## FDA-Approved Pediatric Indications

Fluoxetine is approved for major depressive disorder in children aged eight and older and for obsessive-compulsive disorder in children aged seven and older. Escitalopram is approved for major depressive disorder in adolescents aged twelve and older. Sertraline is approved for OCD in children aged six and older. Fluvoxamine is approved for OCD in children aged eight and older. Duloxetine is approved for generalized anxiety disorder in children aged seven and older. Many other uses in pediatric psychiatry are off-label but supported by evidence, including the use of sertraline for anxiety disorders and SSRIs for PTSD.

| Medication | Class | FDA-Approved Pediatric Indication(s) | Approved Age | Starting Dose | Target Dose | Maximum Dose |
|---|---|---|---|---|---|---|
| Fluoxetine | SSRI | MDD, OCD | 8+ (MDD), 7+ (OCD) | 10 mg | 20 mg | 60-80 mg |
| Escitalopram | SSRI | MDD | 12+ | 5 mg | 10 mg | 20 mg |
| Sertraline | SSRI | OCD | 6+ | 25 mg | 50-100 mg | 200 mg |
| Fluvoxamine | SSRI | OCD | 8+ | 25 mg | 50-200 mg | 200 mg |
| Duloxetine | SNRI | GAD | 7+ | 30 mg | 30-60 mg | 120 mg |

## Evidence Base for Pediatric Use

### Depression

The landmark Treatment for Adolescents with Depression Study demonstrated that fluoxetine combined with CBT was superior to either treatment alone for adolescent depression. Escitalopram showed efficacy in adolescent major depressive disorder in two randomized controlled trials. Other SSRIs have produced mixed results in pediatric depression trials. The number needed to treat for SSRIs in pediatric depression is approximately ten, reflecting a more modest effect size than is seen in anxiety.

### Anxiety Disorders

The Child/Adolescent Anxiety Multimodal Study showed that sertraline, CBT, and their combination were all effective for childhood anxiety, with the combination being superior to either treatment alone. SSRIs demonstrate efficacy across generalized anxiety disorder, social anxiety disorder, and separation anxiety disorder. The number needed to treat for SSRIs in pediatric anxiety is approximately three to four, reflecting a considerably stronger effect size than in depression. Duloxetine is the only SNRI with FDA approval for pediatric anxiety, specifically for generalized anxiety disorder.

### OCD

SSRIs are considered first-line pharmacotherapy for pediatric OCD alongside exposure and response prevention. Higher doses are often required for OCD compared to the doses used for depression. Fluvoxamine, fluoxetine, and sertraline have the strongest pediatric evidence base. Augmentation with low-dose antipsychotics may be considered for treatment-refractory cases.

## The FDA Black Box Warning

In 2004, the FDA issued a black box warning for all antidepressants used in patients under twenty-five, based on a meta-analysis showing an increased risk of suicidal ideation and behavior at a rate of 4% compared to 2% on placebo. No completed suicides occurred in the clinical trials that informed the warning. Paradoxically, the warning led to a significant decline in antidepressant prescribing that coincided with an increase in adolescent suicide rates, suggesting that the unintended consequence of fewer treated depressed adolescents may have been more harmful than the small medication-associated risk. Clinicians must balance the risk of untreated depression, which itself carries high suicide risk, against the medication-related risk.

### Clinical Implications

Informed consent should include a discussion of the black box warning. Close monitoring during initiation and dose changes is essential. The activation syndrome, characterized by agitation, insomnia, restlessness, and impulsivity, may mimic or precede suicidality and should be watched for carefully. The recommended monitoring schedule involves weekly follow-up for the first month, biweekly contact for the second month, and monthly visits thereafter.

## Prescribing Guidelines

### Starting and Titrating

Treatment should begin at the lowest available dose with gradual titration. Adequate time for response must be allowed: four to six weeks at a therapeutic dose for depression and eight to twelve weeks for OCD. For fluoxetine, the typical starting dose is 10 mg daily with a target of 20 mg and a maximum of 60-80 mg. For sertraline, the starting dose is 25 mg daily with a target of 50-100 mg and a maximum of 200 mg. For escitalopram, the starting dose is 5 mg daily with a target of 10 mg and a maximum of 20 mg.

### Duration of Treatment

Treatment should continue for at least six to twelve months after symptom remission for depression. OCD may require longer-term maintenance treatment. When discontinuation is appropriate, the medication should be tapered gradually over weeks to months to avoid discontinuation syndrome, which can include dizziness, nausea, irritability, electric shock sensations commonly called "brain zaps," and flu-like symptoms.

## Adverse Effects

### Common Side Effects

Gastrointestinal symptoms including nausea, diarrhea, and abdominal pain are common but usually transient. Headache and dizziness occur frequently. Sleep disturbance may present as either insomnia or somnolence depending on the specific agent. Behavioral activation, manifesting as restlessness, agitation, and disinhibition, is more common in younger children. Sexual dysfunction is a concern in adolescents though often underreported.

### Serious Adverse Effects

Serotonin syndrome is rare but life-threatening, presenting with confusion, agitation, myoclonus, hyperthermia, and autonomic instability. Hyponatremia due to SIADH can occur, particularly when SSRIs are combined with other serotonergic agents. QTc prolongation is a concern particularly with citalopram at high doses. Increased bleeding risk results from serotonin's effects on platelet function. A switch to mania or hypomania may occur in patients with undiagnosed bipolar disorder.

### SNRI-Specific Concerns

Venlafaxine carries risks of dose-dependent hypertension, higher rates of suicidal ideation in pediatric trials compared to other antidepressants, and a particularly difficult discontinuation process. Duloxetine carries a hepatotoxicity risk and should be avoided in patients with hepatic impairment. Both SNRIs may cause more activation and more severe discontinuation symptoms than SSRIs.

## Monitoring Protocol

At baseline, clinicians should assess height, weight, vital signs, mood, suicidality, and concomitant medications. During weeks one through four, weekly contact, either in person or by phone, should assess for activation, suicidality, and side effects. During weeks five through eight, biweekly assessment of response and tolerability is appropriate. Monthly visits should continue until the patient is stable, after which quarterly monitoring is sufficient. Standardized rating scales such as the PHQ-A, SCARED, and Columbia Suicide Severity Rating Scale should be used at each visit.

## Clinical Pearls

Fluoxetine remains the best-studied and first-choice SSRI for pediatric depression. Its long half-life reduces the risk of discontinuation syndrome but prolongs drug interactions. The black box warning should inform clinical practice but not deter prescribing when clinically indicated, because untreated depression carries greater risk than appropriately monitored SSRI therapy. Behavioral activation in the first weeks of treatment is common in children and may be mistaken for worsening illness; dose reduction or switching is preferable to abrupt discontinuation. Combining SSRIs with evidence-based psychotherapy, particularly CBT, yields the best outcomes for both depression and anxiety disorders.

## References

1. March, J. S., Silva, S., Petrycki, S., et al. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS). *JAMA*, 292(7), 807-820.
2. Walkup, J. T., Albano, A. M., Piacentini, J., et al. (2008). Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. *New England Journal of Medicine*, 359(26), 2753-2766.
3. Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. *Archives of General Psychiatry*, 63(3), 332-339.
4. Strawn, J. R., Welge, J. A., Wehry, A. M., et al. (2015). Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. *Depression and Anxiety*, 32(3), 149-157.